NRIX · NASDAQ
Nurix Therapeutics, Inc.
$15.88 -9.87 (-38.23%)
Company overview
Nurix Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for relapsed or refractory B-cell malignancies, and NX-5948, an orally bioavailable BTK degrader for relapsed or refractory B-cell malignancies and autoimmune diseases. It also develops NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications; NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255, which is in Phase 1 clinical trials for gynecologic cancers including ovarian, endometrial, and cervical cancer. Nurix has strategic collaboration agreements with Gilead Sciences, Inc. and Sanofi S.A.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $1.7B
- Employees
- 286
- Headquarters
- San Francisco, CA
- Website
- nurixtx.com
- CEO
- Arthur T. Sands
- Listed
- July 24, 2020
- P/E
- -5.03
- Dividend yield
- 0.00%
Company financials
- Revenue
- $71.8M
- Gross profit
- -$100M
- Operating income
- -$315M
- EBITDA
- -$289M
- Net income
- -$295M
- EPS
- -$3.16
- Total assets
- $636M
- Total debt
- $58.7M
- Gross margin
- -139.43%
- Net margin
- -411.37%
- Earnings yield
- -19.90%
No geographic segmentation.
Showing FY 2025
NRIX
1D
NASDAQ
O17.16H17.28L14.78C15.95-9.87 (-38.23%)Vol18.05M
News